Orion Holdings subsidiary invests 82.5B KRW in Ligacem Bio
오리온홀딩스
001800
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=703
Risk-adjusted indicator based on 703 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Acquisition Amount: 82,499,895,400 KRW
- • Acquired Shares: 552,578 Shares
- • Post-acquisition Ownership: 9,915,861 Shares (25.28%)
- • Acquisition Ratio to Total Assets: 1.33%
- • Target Company 2026 Capital: 18,509,709,000 KRW
AI Analysis Summary
ORION Holdings' subsidiary, PAN ORION Corp. Limited, will acquire 552,578 convertible preferred shares of Ligacem Bioscience for 82.5 billion KRW, representing 1.33% of ORION Holdings' total assets. This investment will increase PAN ORION's stake in Ligacem Bioscience to 25.28% (9,915,861 shares) and is aimed at participating in a strategic industry fund. The acquisition is expected by July 24, 2026, via cash. Ligacem Bioscience reported a net loss of 91.55 billion KRW in the current year, indicating a long-term strategic play rather than immediate financial returns. The convertible preferred shares have a 10-year term and a conversion price of 149,300 KRW per share, with potential for upward and downward adjustments.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.